SACQ (170) | SQCQ (187) | |||||
---|---|---|---|---|---|---|
Flare (56) | Non-flare (114) | p | Flare (29) | Non-flare (158) | p | |
Age at diagnosis (years) | 30.95 ± 13.88 | 32.65 ± 14.61 | 0.469 | 34.19 ± 14.14 | 39.42 ± 15.15 | 0.086 |
Gender (male to female) | 8:48 | 13:101 | 0.624 | 2:27 | 17:141 | 0.765 |
Recurrence time or follow-up timea (months) | 21.82 (13.39, 31.59) | 19.23 (10.02, 34.32) | 0.440 | 26.43 (16.72, 41.97) | 22.92 (11.63, 43.65) | 0.361 |
Duration of serological activity/inactivity before SACQ/SQCQ (months) | 13.58 (6.94, 25.19) | 15.49 (7.31, 25.87) | 0.771 | 11.10 (5.77, 21.72) | 8.88 (3.01, 15.99) | 0.115 |
Time to SACQ/SQCQb (months) | 23.88 (13.03, 50.68) | 22.07 (12.16, 50.62) | 0.562 | 21.0 (11.85, 58.65) | 17.28 (9.84, 36.53) | 0.241 |
Dose of corticosteroids at the start of SACQ/SQCQ | 7.5 (5.0, 7.5) | 7.5 (6.25, 7.5) | 0.096 | 7.5 (5.0, 7.5) | 7.5 (5.0, 7.5) | 0.608 |
Taking antimalarials at the start of SACQ/SQCQ | 40/56 (71.4%) | 90/114 (78.9%) | 0.277 | 22/29 | 132/158 | 0.319 |
Taking immunosuppressants at the start of SACQ/SQCQ | 29/56 (51.8%) | 67/114 (58.8%) | 0.414 | 15/29 | 84/158 | 0.886 |
Dose of corticosteroidsc (mg) when relapsed or at the end of follow-up | 5.0 (2.81,7.5) | 3.75 (1.25, 5.0) | 0.011 | 5.0 (0, 5.0) | 3.75 (1.25, 5.0) | 0.489 |
Taking antimalarials when relapsed or at the end of follow-up | 36/56 (64.3%) | 97/114 (85.1%) | 0.002 | 17/29 (58.6%) | 135/158 (85.4%) | 0.001 |
Taking immunosuppressants when relapsed or at the end of follow-up | 23/56 (41.1%) | 69/114 (60.5%) | 0.017 | 10/29 (34.5%) | 87/158 (55.1%) | 0.041 |
Anti-dsDNA (+) | 41/56 (73.2%) | 96/114 (84.2%) | 0.101 | — | — | — |
Hypocomplementemia | 26/56 (46.4%) | 36/114 (31.6%) | 0.064 | — | — | — |
Symptoms at initial diagnosis. | ||||||
LN | 16/56 (28.6%) | 46/114 (40.4%) | 0.175 | 10/29 (34.5%) | 58/158 (36.7%) | 0.819 |
NPSLE | 2/56 (3.6%) | 6/114 (5.3%) | 1.000 | 1/29 (3.4%) | 10/158 (6.3%) | 0.860 |
Thrombocytopenia | 9/56 (16.1%) | 14/114 (12.3%) | 0.485 | 6/29 (20.7%) | 30/158 (19.0%) | 0.831 |
Hemolytic anemia | 5/56 (8.9%) | 9/114 (7.9%) | 0.776 | 1/29 (3.4%) | 13/158 (8.2%) | 0.606 |
Pulmonary hypertension | 3/56 (5.4%) | 1/114 (0.9%) | 0.105 | 1/29 (3.4%) | 4/158 (2.5%) | 1.000 |
Myocardial involvement | 0/56 (0) | 0/114 (0) | NA | 0/29 (0) | 3/158 (1.9%) | 1.000 |
ILD | 2/56 (3.6%) | 1/114 (0.9%) | 0.253 | 0/29 (0) | 6/158 (3.8%) | 0.622 |
Alveolar hemorrhage | 0/56 (0) | 0/114 (0) | NA | 0/29 (0) | 0/29 (0) | NA |
Smooth muscle involvement | 0/56 (0) | 6/114 (5.3%) | 0.179 | 0/29 (0) | 5/158 (3.2%) | 0.730 |
Polyserositis | 2/56 (3.6%) | 6/114 (5.3%) | 1.000 | 1/29 (3.4%) | 7/158 (4.4%) | 1.000 |
APS | 2/56 (3.6%) | 5/114 (4.4%) | 1.000 | 1/29 (3.4%) | 4/158 (2.5%) | 1.000 |
TTP or TMA | 0/56 (0) | 0/114 (0) | NA | 0/29 (0) | 0/29 (0) | NA |
Secondary SS | 5/56 (8.9%) | 14/114 (12.3%) | 0.611 | 3/29 (10.3%) | 22/158 (13.9%) | 0.823 |